<SEC-DOCUMENT>0001193125-24-147011.txt : 20240524
<SEC-HEADER>0001193125-24-147011.hdr.sgml : 20240524
<ACCEPTANCE-DATETIME>20240524160248
ACCESSION NUMBER:		0001193125-24-147011
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20240524
DATE AS OF CHANGE:		20240524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279711
		FILM NUMBER:		24984155

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d822027ds3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML><HEAD>
<TITLE>Form S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on May 24, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>ELEDON PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-1000967</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>19800 MacArthur Blvd., Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Irvine, California 92612 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(949) <FONT STYLE="white-space:nowrap">238-8090</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>David-Alexandre C. Gros, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Eledon Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>19800 MacArthur Blvd., Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Irvine, California 92612 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(949) <FONT STYLE="white-space:nowrap">238-8090</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mark
Peterson </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Shelly Heyduk </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>O&#146;Melveny&nbsp;&amp; Myers LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>610 Newport Center Drive, Suite 1700 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Newport Beach, California 92660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(949) <FONT STYLE="white-space:nowrap">823-6900</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><B>Approximate
date of commencement of proposed sale to the public</B>: From time to time, after the effective date of this Registration Statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this
Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Commission acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion, dated May 24, 2024 </B></FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS </U></B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g822027g95p03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>21,100,000 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the
resale from time to time of up to 21,100,000 shares of our common stock, $0.001 par value per share (the &#147;Shares&#148;), by the selling stockholders identified in this prospectus (collectively with any of the holders&#146; transferees,
pledgees, donees or successors, the &#147;Selling Stockholders&#148;), pursuant to a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) between Eledon Pharmaceuticals, Inc. (the &#147;Company&#148;) and the Selling Stockholders,
which consist of 13,110,484 shares of our common stock held by the Selling Stockholders and 7,989,516 shares of our common stock issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares
of our common stock held by certain Selling Stockholders <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;). The Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants described in the preceding sentence were
issued in the closing of a private placement completed on May&nbsp;9, 2024 pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of the Shares by the Selling
Stockholders may occur at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The Selling Stockholders may sell
Shares to or through underwriters, broker dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the Selling Stockholders, the purchasers of the Shares, or both. If required, the number of Shares to
be sold, the public offering price of those Shares, the names of any underwriters, broker dealers or agents and any applicable commission or discount will be included in a supplement to this prospectus, called a prospectus supplement. See the
disclosure under the heading &#147;Plan of Distribution&#148; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Shares hereunder. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not receive any proceeds from the sale by the Selling Stockholders of the Shares. We will, however, receive the cash exercise price of $0.001
per share for the exercise of any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. If any of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercised on a net exercise cashless basis, we would not receive any cash
payment from the applicable Selling Stockholder upon any such exercise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are paying the cost of registering the Shares covered by this prospectus as
well as various related expenses. The Selling Stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of the Shares. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s common stock is traded on The Nasdaq Capital Market under the symbol &#147;ELDN.&#148; On May&nbsp;23, 2024, the closing sale price of our
common stock was $2.89 per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive offices are located at 19800 MacArthur Boulevard, Suite 250, Irvine, California 92612, and our telephone
number is (949) <FONT STYLE="white-space:nowrap">238-8090.</FONT> </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock
involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading &#147;<A HREF="#tx822027_4">Risk Factors</A>&#148; beginning on page 5 of this prospectus, and under similar headings in the
other documents that are filed after the date hereof and incorporated by reference into this prospectus. </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>This prospectus is dated &#8195;&#8195;&#8195;&#8195;,&nbsp;2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx822027_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an
investment in the securities of Eledon Pharmaceuticals, Inc. See &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; for additional information. You should rely only on the information
contained in or incorporated by reference in this prospectus or a prospectus supplement. The Company has not authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers and sales of these
securities are permitted. You should assume that information contained in this prospectus, or in any document incorporated by reference, is accurate only as of any date on the front cover of the applicable document. Our business, financial
condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references to the terms &#147;Eledon,&#148;
&#147;our,&#148; &#147;us,&#148; &#147;we,&#148; or the &#147;Company&#148; refer to Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) and all wholly owned subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus contains &#147;forward-looking statements&#148; as defined by the Private
Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements of historical or current fact in this prospectus are forward looking statements. In some instances, you can
identify forward-looking statements by the use of words such as &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;estimates,&#148; &#147;intends,&#148; &#147;predicts,&#148; &#147;projects,&#148;
&#147;targets,&#148; &#147;could,&#148; &#147;may,&#148; and similar expressions, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements about our future
expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, our
capital resources and ability to finance planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are inherently uncertain, and actual results may differ
materially from those indicated by such forward-looking statements as a result of various factors, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions
with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials; risks related to the sufficiency of our capital resources to fund planned clinical trials; and other risks and uncertainties discussed in
our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as revised or supplemented by our subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and other filings with the U.S. Securities and
Exchange Commission (the &#147;SEC&#148; or &#147;Commission&#148;), which can be found at www.sec.gov. Any forward-looking statements contained in this prospectus speak only as of the date hereof and not of any future date, and the Company
expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eledon is a clinical stage biopharmaceutical
company using its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (&#147;ALS&#148;). Our lead
compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tegoprubart is engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40
approaches. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen
presenting cells such as macrophages and dendritic cells, as well as B cells. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy
compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which
may play a therapeutic role in autoimmune diseases and in the prevention of allograft rejection after solid organ transplantation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tegoprubart is
designed to negate the risk of thrombolytic events seen in the first generation of anti-CD40L antibodies by introducing structural modifications that have been shown in preclinical models to eliminate binding to the
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> receptors associated with platelet activation without altering the binding of tegoprubart to CD40L. In <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies, dosing of tegoprubart up to
200 mg/kg per week for 26 weeks, demonstrated no adverse events regarding coagulation, platelet activation or thromboembolism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business strategy is
to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a focused immunology franchise. Our strategy is to develop tegoprubart for the prevention of allograft and xenograft rejection, and for
the treatment of autoimmune diseases such as ALS. We selected our indications based on preclinical and clinical data that was generated with either tegoprubart or historical anti-CD40L molecules. In January 2023, we announced our decision to
prioritize resources on our kidney transplantation programs, and discontinue the Company funding of the islet cell transplantation program and the IgAN program. We remain committed to further progressing ALS clinical development and are working with
key stakeholders on potential next steps to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While inhibition of CD40L has shown it may play an important role in immunosuppression in allograft
kidney transplantation, this mechanism of action has also demonstrated that it may be a promising option in xenotransplantation (i.e., transplanting an organ from an animal to a human). In January 2023, we entered into a non-exclusive collaborative
research agreement with eGenesis, Inc. (&#147;eGenesis&#148;), under which eGenesis gained access to tegoprubart for preclinical and clinical xenotransplantation studies in support of eGenesis&#146; kidney, heart and islet xenotransplantation
programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2024,
Eledon entered into the Purchase Agreement with the Selling Stockholders, pursuant to which we agreed to issue and sell to the Selling Stockholders in a private placement, which closed on May&nbsp;9, 2024, 13,110,484 shares of the Company&#146;s
common stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants exercisable for up to an aggregate of 7,989,516 shares of the Company&#146;s common stock, subject to customary adjustments as provided in the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable immediately upon issuance at an exercise price of $0.001 per share and until exercised in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Selling Stockholder may not exercise any portion of a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant to the extent such exercise for common stock would cause such Selling Stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed a beneficial ownership limitation specified by each
Selling Stockholder upon issuance of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (which was set by the applicable Selling Stockholder at 4.99% or 9.99% of our then outstanding common stock following such exercise). Upon at least
61 days&#146; prior notice from the holder to the Company, a holder may increase the applicable beneficial ownership limitation, but in no case above 19.99% of the number of shares of common stock outstanding immediately after giving effect to such
exercise to the extent required under Nasdaq Marketplace Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities issued and issuable pursuant to the Purchase Agreement were not initially
registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and were offered pursuant to the exemption from registration provided in Section&nbsp;4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the private placement, the Company also entered into a registration rights agreement, dated May&nbsp;6, 2024 (the &#147;Registration
Rights Agreement&#148;), with the Selling Stockholders, pursuant to which, among other things, the Company agreed to prepare and file with the SEC, within 20 days after the date of the Registration Rights Agreement, a registration statement to
register for resale the shares of our common stock issued and issuable under the Purchase Agreement and the shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued pursuant to the
Purchase Agreement, and to cause the registration statement to become effective within a specified time after its initial filing with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otic Pharma, Ltd.
(&#147;Otic&#148;) was founded in the State of Israel in 2008. In 2015, Otic established U.S. operations and moved its corporate headquarters to Irvine, California. In 2017, Otic consummated a reverse merger with Tokai Pharmaceuticals, Inc.
(&#147;Tokai&#148;), a Delaware corporation that was incorporated on March&nbsp;26, 2004, pursuant to which, among other things, Tokai purchased from Otic and its stockholders all of the common and preferred shares of Otic in exchange for the
issuance of a certain number of shares of common stock of Tokai (the &#147;Reverse Merger&#148;). Following the Reverse Merger, Tokai changed its name to Novus Therapeutics, Inc. On September&nbsp;14, 2020, we acquired Anelixis, after which Anelixis
became a wholly owned subsidiary of the Company. On January&nbsp;4, 2021, we changed our name from Novus Therapeutics, Inc. to Eledon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive offices are located at 19800 MacArthur Boulevard, Suite 250, Irvine, California 92612. We also have a research and development office in
Burlington, Massachusetts. Our telephone number is (949) <FONT STYLE="white-space:nowrap">238-8090</FONT> and our website is www.eledon.com. The information contained in, or accessible through, our website does not constitute part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before making an investment decision, you should carefully consider the risks described under &#147;Risk Factors&#148; in the applicable prospectus
supplement, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial
circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your
investment. This prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a
result of certain factors, including the risks mentioned elsewhere in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading &#147;Risk Factors&#148; included in our most recent Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as revised or supplemented by our subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated herein by reference, together with the other
information contained in this prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus. We expect to update these Risk Factors from time to time in the periodic and current reports we file with the SEC
after the date of this prospectus. These updated Risk Factors will be incorporated by reference in this prospectus. If any of these risks occur, our business, financial condition, results of operations and future growth prospects could be materially
and adversely affected. In these circumstances, the trading price of our securities could decline, and you may lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from the resale of the Shares under this prospectus are solely for the accounts of the Selling Stockholders. We will not receive any proceeds
from the sale of Shares under this prospectus. We will, however, receive the cash exercise price of $0.001 per share for the exercise of any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. If any of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercised on a net exercise cashless basis, we would not receive any cash payment from the applicable Selling Stockholder upon any such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares being offered by the Selling Stockholders are those previously issued to the Selling Stockholders and those issuable to the Selling Stockholders
upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. For additional information regarding the issuance of the Shares, see &#147;The Company&#151;Private Placement&#148; above. We are registering the Shares in order to
permit the Selling Stockholders to offer the Shares for resale from time to time. Except for the ownership of the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and as otherwise described below under &#147;Certain
Relationships with the Selling Stockholders,&#148; the Selling Stockholders have not had any material relationship with us within the past three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration Rights Agreement with the Selling Stockholders, this prospectus generally covers the resale of the sum of
(i)&nbsp;the number of shares of common stock issued to the Selling Stockholders pursuant to the Purchase Agreement and (ii)&nbsp;the maximum number of shares of common stock issuable upon exercise of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued pursuant to the Purchase Agreement, determined as if the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were exercised in full as of the trading day immediately
preceding the applicable date of determination and all subject to adjustment as provided in the Registration Rights Agreement, without regard to any limitations on the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, a Selling Stockholder may not exercise any portion of a <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to the extent such exercise for common stock would cause such Selling Stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed a
beneficial ownership limitation specified by each Selling Stockholder upon issuance of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (which was generally set at 4.99% or 9.99% of our then outstanding common stock following such
exercise). Upon at least 61 days&#146; prior notice from the holder to the Company, a holder may increase the applicable beneficial ownership limitation, but in no case above 19.99% of the number of shares of common stock outstanding immediately
after giving effect to such exercise to the extent required under Nasdaq Marketplace Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the Selling Stockholders and other
information regarding the beneficial ownership of our common stock by each of the Selling Stockholders. For purposes of the table below, we have assumed that the Selling Stockholders will be able to sell in this offering all shares of common stock
issued pursuant to the Purchase Agreement or upon the exercise of any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued to the Selling Stockholder without regard to any beneficial ownership limitations. The Selling Stockholders may
sell all, some or none of their shares in this offering. See &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the
rules and regulations of the SEC based on 38,506,614 shares of common stock outstanding as of May 23, 2024. In computing the number of common shares beneficially owned by a person and the percentage ownership of that person, we also deemed
outstanding shares of common stock issuable upon the exercise of warrants or other convertible securities held by that Selling Stockholder that are exercisable or convertible within 60&nbsp;days of May 23, 2024, including the warrants, but subject
to any applicable beneficial ownership limitation. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. The inclusion of any shares in this table does not constitute an
admission of beneficial ownership for any Selling Stockholder named below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are relying on written commitments from the Selling Stockholders to notify us of any changes in their
beneficial ownership after the date they originally provided this information. See &#147;Plan of Distribution.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Maximum&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;to&nbsp;be&nbsp;Sold<BR>Pursuant to this</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Owned&nbsp;After&nbsp;Offering&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Owned&nbsp;Prior&nbsp;to&nbsp;Offering&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prospectus (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with BVF Partners L.P. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,343,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,016,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,326,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ZP Master Cap Fund, Ltd. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,109,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,109,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schonfeld Global Master Fund L.P.&nbsp;(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera Biotech Master Fund LP&nbsp;(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,317,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund, L.P. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JDRF T1D Fund LLC (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,586,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,164,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners Limited Partnership (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCP RFM LP (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC&#151;Series&nbsp;A&nbsp;(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Matthew D. Perry and Stacy E. Perry Revocable Trust Dated 10/1/2009 (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars Bader (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,541,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">709,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deschutes I, LP (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Rohlinger Family Living Trust 2/14/08 (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LTD-III</FONT> LLC (16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Friedman 2008 Revocable Trust (17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blu-G Nevada Par Equity LLC dba BGN Investing 1 (18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blu-B Nevada Par Equity LLC dba BBN Investing 1 (19)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc Wolff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">StoneX Financial Inc C/F Erick Richardson Jr. IRA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Newpath Partners III, LP (20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">843,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">843,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HC Diversified Strategies LP (21)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,797,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,797,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21,100,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent (1%) of the Company&#146;s outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If required, information about other selling stockholders, except for any future transferees, pledgees, donees
or successors of the Selling Stockholders named in the table above, will be set forth in a prospectus supplement or amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments to the
registration statement will be filed to disclose any material changes to the plan of distribution from the description contained in the final prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) the maximum number of Shares of common stock being offered pursuant to this prospectus by each
applicable Selling Stockholder and (ii) if applicable, any other shares of Eledon common stock beneficially owned by such Selling Stockholder as of May 23, 2024, including any shares of common stock issuable upon exercise of warrants held by the
Selling Stockholder, subject to any applicable beneficial ownership limitations applicable to such securities as described in the footnotes herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maximum Shares of common stock being offered pursuant to this prospectus by the Selling Stockholders
consists of the number of shares of common stock issued or issuable to the Selling Stockholder pursuant to the Purchase Agreement, assuming that all <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued under the Purchase Agreement were
exercised in full as of the trading day immediately preceding such date and without regard to any applicable beneficial ownership limitations under the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all of the Shares offered by the Selling Stockholders pursuant to this prospectus without
regard to any beneficial ownership limitations applicable to the ownership of such Shares and that the Selling Stockholders buy or sell no additional shares of common stock prior to the completion of the offering. The beneficial ownership numbers
and percentages give effect to the impact of any beneficial ownership limitations applicable to any other securities owned by the Selling Stockholders as described in the footnotes herein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of common stock being offered by Selling Stockholders affiliated with BVF Partners L.P.
pursuant to this prospectus consists of the following: (i) an aggregate of 4,204,520 shares of common stock being offered pursuant to this prospectus by Biotechnology Value Fund, L.P. (&#147;BVF&#148;), which includes 3,173,135&nbsp;shares issuable
upon exercise of Pre-Funded Warrants, (ii) an aggregate of 3,347,359 shares of common stock being offered pursuant to this prospectus by Biotechnology Value Fund II, L.P. (&#147;BVF2&#148;), which included 2,526,238&nbsp;shares issuable upon
exercise of Pre-Funded Warrants, (iii) an aggregate of 307,499 shares of common stock being offered pursuant to this prospectus by Biotechnology Value Trading Fund OS LP (&#147;Trading Fund OS&#148;), which included 232,068 shares issuable upon
exercise of Pre-Funded Warrants, and (iv) an aggregate of 157,499 shares of common stock being offered pursuant to this prospectus by MSI BVF SPV, LLC (&#147;MSI BVF&#148; and, together with BVF, BVF2 and Trading Fund OS, the &#147;BVF
Stockholders&#148;), which includes 118,864 shares issuable upon exercise of Pre-Funded Warrants, in each case without regard to any beneficial ownership limitations applicable to the ownership of such Shares. Based on information provided to the
Company by the Selling Stockholder and information provided in a Schedule 13G/A filed by BVF on February 14, 2024, the number of shares of common stock in the columns &#147;Shares of Common Stock Owned Prior to the Offering&#148; and &#147;Shares of
Common Stock Owned After Offering&#148; also include the following: (i) 2,330,418 shares of common stock held by BVF, (ii)&nbsp;1,812,558&nbsp;shares of common stock held by BVF2, (iii) 145,029 shares of common stock held by Trading Fund OS, and
(iv) 38,705 shares of common stock held in a certain Partners Managed Account through MSI BVF (the &#147;Partners Managed Account&#148;). BVF I GP LLC (&#147;BVF GP&#148;), as the general partner of BVF, may be deemed to beneficially own the shares
beneficially owned by BVF. BVF II GP LLC (&#147;BVF2 GP&#148;), as the general partner of BVF2, may be deemed to beneficially own the shares beneficially owned by BVF2. BVF&nbsp;Partners OS Ltd. (&#147;Partners OS&#148;), as the general partner of
Trading Fund OS, may be deemed to beneficially own the shares beneficially owned by Trading Fund OS. BVF GP Holdings LLC (&#147;BVF GPH&#148;), as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the shares
beneficially owned in the aggregate by BVF and BVF2. BVF Partners L.P. (&#147;Partners&#148;), as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the shares beneficially
owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners. Mark Lampert, as a director
and officer of BVF, Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. BVF GP disclaims beneficial ownership of the shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the shares beneficially
owned by BVF2. Partners OS disclaims beneficial ownership of the shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr.&nbsp;Lampert
disclaims beneficial ownership of the shares beneficially owned by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account. The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; in the table do not include shares of common stock issuable upon conversion of Series X1 non-voting convertible preferred stock, $0.001 par value per share, and Series X non-voting convertible preferred stock, $0.001
par value per share (collectively, the &#147;convertible preferred stock&#148;) and certain warrants held by certain of the foregoing entities. Such convertible preferred stock and warrants are each subject to a beneficial ownership limitation of
9.99%, which does not permit the foregoing entities to convert or exercise that portion of the convertible preferred stock or warrants, as applicable, that would result in the entities owning, after conversion or exercise, a number of shares of
common stock in excess of the beneficial ownership limitation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, ZP Master MidCap Fund, Ltd. (the
&#147;Fund&#148;) has delegated to Zimmer Partners, LP, as investment manager (the &#147;Investment Manager&#148;), sole voting and investment power over the shares of common stock held by the Fund pursuant to its investment management agreement
with Zimmer Partners, LP. As a result, each of the Investment Manager, Zimmer Partners, GP, as the general partner of the Investment Manager, Zimmer Financial Services Group, LLC, as the sole member of Zimmer Partners GP, LLC, and Stuart J. Zimmer,
as the managing member of Zimmer Financial Services Group, LLC, may be deemed to exercise voting and investment power over the shares held by the Fund and thus may be deemed to beneficially own such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Ryan Tolkin, CEO and CIO of Schonfeld
Strategic Advisors LLC, may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, other than the shares of common stock
being offered pursuant to this prospectus, the Selling Stockholder beneficially owns 67,279&nbsp;shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Alyeska Investment Group, L.P., the
investment manager of the Selling Stockholder, has voting and investment control of the shares held by the Selling Stockholder. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to beneficially own the
shares owned by the Selling Stockholder. Mr. Parekh, disclaims any beneficial ownership of the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 1,082,250 shares of common stock issuable within 60 days of May&nbsp;23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling
Stockholder, Steven St. Peter may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Nantahala Capital Management, LLC has
been delegated the legal power to vote and/or direct the disposition of securities on behalf of the Selling Stockholder as a general partner or investment manager and may be deemed to beneficially own the shares owned by the Selling Stockholder.
Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Matthew D. Perry may be deemed to
beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, other than the shares of common stock
being offered pursuant to this prospectus, the Selling Stockholder beneficially owns 832,689&nbsp;shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 43,290 shares of common stock issuable within 60 days of May 23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling Stockholder,
Robert J. Levitt may be deemed to beneficially own the shares owned by the Selling Stockholder.<B></B> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 43,290 shares of common stock issuable within 60 days of May 23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling Stockholder,
George J. Rohlinger may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Nathan Snyder may be deemed to
beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 43,290 shares of common stock issuable within 60 days of May 23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling Stockholder,
Richard Stanley Friedman may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 108,225 shares of common stock issuable within 60 days of May&nbsp;23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling
Stockholder, Charles-Edouard Gros, who is the brother of Eledon&#146;s Chief Executive Officer, David-Alexandre Gros, may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Owned Prior to Offering&#148; and &#147;Shares of Common
Stock Owned After Offering&#148; includes 21,645 shares of common stock issuable within 60 days of May 23, 2024 upon the exercise of warrants held by the Selling Stockholder. Based on information provided to the Company by the Selling Stockholder,
Shlomo Boehm may be deemed to beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Thomas Cahill may be deemed to
beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided to the Company by the Selling Stockholder, Marc Wolff may be deemed to
beneficially own the shares owned by the Selling Stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships with the Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2024,
in connection with the Purchase Agreement, the Company entered into the Registration Rights Agreement with the Selling Stockholders. Pursuant to the Registration Rights Agreement, the Company agreed, among other things, to prepare and file with the
SEC a registration statement to register for resale the shares of our common stock issued and issuable to the Selling Stockholders pursuant to the Purchase Agreement and to cause the registration statement to become and remain effective within the
time periods specified in the Registration Rights Agreement. We have also agreed, among other things, to indemnify the Selling Stockholders and their officers, directors, members, partners, agents, brokers, investment advisors and employees from
certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prior
Financing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>January 2022 Exchange Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2022, Eledon entered into an exchange agreement with the BVF Stockholders, pursuant to which such stockholders exchanged 550,000 shares of
the Company&#146;s common stock for 9,899.99 shares of Series X<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> non-voting convertible preferred stock, $0.001 par value per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2023 Private Placement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;28, 2023, Eledon
entered into a securities purchase agreement with the selling stockholders identified therein, pursuant to which we agreed to issue and sell to such selling stockholders in a private placement: (a)&nbsp;in an initial closing, which closing occurred
on May&nbsp;5, 2023, (i) 8,730,168 shares of the Company&#146;s common stock, <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants exercisable for up to an aggregate of 6,421,350 shares of the Company&#146;s common stock, and
(iii)&nbsp;common warrants exercisable for up to an aggregate of 15,151,518 shares of the Company&#146;s common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof); (b) in a second closing, subject to the
satisfaction or waiver of certain conditions set forth in the securities purchase agreement, 20,202,024 shares of common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof); and (c)&nbsp;in a third closing, subject
to the satisfaction or waiver of certain conditions set forth in the securities purchase agreement, 25,252,530 shares of common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof), in each case subject to customary
adjustments as provided in the securities purchase agreement, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant or common warrant, as applicable. Certain of the Selling Stockholders or affiliated entities or individuals participated as
investors in the securities purchase agreement transactions described above, including the BVF Stockholders, JDRF T1D Fund, LLC, Deschutes I, LP, The Rohlinger Family Living Trust 2/14/08, <FONT STYLE="white-space:nowrap">LTD-III</FONT> LLC, Richard
Friedman 2008 Revocable Trust, Blu-G Nevada Par Equity LLC dba BGN Investing 1, and Blu-B Nevada Par Equity LLC dba BBN Investing 1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Observer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From July 2021 to March 2022, Arman Gupta, an employee of BVF Partners L.P., an affiliate of the BVF Stockholders, served as a
<FONT STYLE="white-space:nowrap">non-voting</FONT> observer on the board of directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder and any of their pledgees, assignees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of the Shares covered hereby on any of the following markets or exchanges on which our common stock is
listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the NYSE American (or any successors to any of the foregoing), or on any other
stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling
securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker dealer as principal and resale by the broker dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to their members, partners or stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker dealers that agree with the Selling Stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may also sell securities under Rule 144 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such rule (&#147;Rule 144&#148;), or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker dealers engaged by the Selling Stockholders may arrange for other broker dealers to participate in
sales. Broker dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a
supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA <FONT
STYLE="white-space:nowrap">IM-2440.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the Shares or otherwise, the Selling Stockholders may enter into hedging
transactions with broker dealers or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The Selling Stockholders may also sell Shares short and deliver these
securities to close out their short positions, or loan or pledge the Shares to broker dealers that in turn may sell such shares. The Selling Stockholders may also enter into option or other transactions with broker dealers or other financial
institutions or create one or more derivative securities which require the delivery to such broker dealer or other financial institution of the Shares offered by this prospectus, which securities such broker dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker dealers or agents that are involved in selling the Shares may be
deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker dealers or agents and any profit on the resale of the Shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to
distribute the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Selling Stockholder that is an entity may elect to make an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of
the Shares to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the Shares. The Company has agreed to
indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to
keep this prospectus effective until the earlier of (i) the date on which all Shares may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 under the
Securities Act, without the requirement for the Company to be in compliance with the current public information under Rule 144 or any other rule of similar effect or (ii) all of the Shares have been sold pursuant to this prospectus or Rule 144 under
the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the Shares covered
hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), any person engaged in the
distribution of the Shares may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the
Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or
any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act, as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the securities in respect of which this prospectus is being delivered will be passed upon for us by O&#146;Melveny&nbsp;&amp; Myers LLP,
Newport Beach, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KMJ Corbin&nbsp;&amp; Company LLP, independent registered public accounting firm, has audited our consolidated financial statements as of and for the years
ended December&nbsp;31, 2023 and 2022, included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 as set forth in their report (which includes an explanatory paragraph regarding the
Company&#146;s ability to continue as a going concern), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our consolidated financial statements are incorporated by reference in reliance on KMJ
Corbin&nbsp;&amp; Company LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC, and we have filed with the SEC a registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of the information included in
the registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and schedules and our reports, proxies,
information statements and other information filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our filings are available to the public on the Internet, through a database maintained
by the SEC at www.sec.gov. We also maintain a website at www.eledon.com. We have included our website address for the information of prospective investors and do not intend it to be an active link to our website. Information contained on our website
does not constitute a part of this prospectus or any applicable prospectus supplement (or any document incorporated by reference herein or therein). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx822027_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We
incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the date of the registration statement of which this prospectus forms a part and
prior to its effectiveness and until the end of any offerings under this prospectus, except for any document or portion thereof deemed to be &#147;furnished&#148; and not filed in accordance with SEC rules: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1404281/000095017024038091/eldn-20231231.htm">March&nbsp;28, 2024</A>, as amended by Amendment No. 1 to Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1404281/000095017024049277/eldn-20231231.htm">April&nbsp;26, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended
March&nbsp;31, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000095017024060025/eldn-20240331.htm">May 15, 2024</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> <A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-20240506.htm">filed
 with the SEC on May&nbsp;7, 2024</A>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex45_320.htm">Exhibit
 4.5</A> of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;31, 2021, as well as any subsequent amendments or reports filed for the purpose of
updating such description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the
date of the original registration statement of which this prospectus forms a part and prior to its effectiveness, provided that all documents &#147;furnished&#148; by the Company to the SEC and not &#147;filed&#148; are not deemed incorporated by
reference herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus
supplement. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front page of
those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in
this prospectus, including exhibits to these documents. You should direct any requests for documents to Eledon Pharmaceuticals, Inc., 19800 MacArthur Boulevard, Suite 250, Irvine, California 92612, telephone:
<FONT STYLE="white-space:nowrap">(949)&nbsp;238-8090.</FONT> </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g822027g95p03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>21,100,000 Shares of Common Stock
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expenses payable by us in connection with the issuance and distribution of the securities being registered (other than underwriting discounts and
commissions, if any) are set forth below. Each item listed is estimated, except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,623.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,623.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Certificate of Incorporation provides for the elimination of personal monetary liability of directors to the fullest extent permissible
under Delaware law. Delaware law does not permit the elimination or limitation of director monetary liability for: (i)&nbsp;breaches of the director&#146;s duty of loyalty to the corporation or its stockholders; (ii)&nbsp;acts or omissions not in
good faith or involving intentional misconduct or knowing violations of law; (iii)&nbsp;the willful or negligent payment of unlawful dividends or unlawful stock repurchases or redemptions or (iv)&nbsp;transactions in which the director received an
improper personal benefit. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law permits a Delaware corporation to indemnify, on certain terms and
conditions, any person who was or is a party or is threatened to be made a party to any threatened pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a
director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action. The Certificate of Incorporation and Bylaws of the Company require the Company to indemnify the
Company&#146;s directors and officers to the fullest extent permitted under Delaware law. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000119312514354857/d793658dex31.htm">Restated Certificate of Incorporation of Novus Therapeutics, Inc., a Delaware corporation, dated September&nbsp;
22, 2014 (incorporated by reference to Exhibit 3.1 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on September&nbsp;26, 2014)
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000119312517170677/d393884dex31.htm">Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a reverse stock-split), filed
with the Secretary of the State of Delaware on May&nbsp;9, 2017 (incorporated by reference to Exhibit 3.1 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on May&nbsp;15, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001404281/000119312517170677/d393884dex32.htm">Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a change in the corporation&#146;s
 name to &#147;Novus Therapeutics, Inc.&#148;), filed with the Secretary of the State of Delaware on May&nbsp;9, 2017 (incorporated by reference to Exhibit 3.2 to the registrant&#146;s current report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on May&nbsp;15, 2017) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000119312520264806/d18987dex31.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a reverse stock-split),
 effective as of October&nbsp;5, 2020 (incorporated by reference to Exhibit 3.1 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on
October&nbsp;6, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000110465921000921/tm211620d1_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a change
 in the corporation&#146;s name to &#147;Eledon Pharmaceuticals, Inc.&#148;), effective as of January&nbsp;5, 2021 (incorporated by reference to Exhibit 3.1 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on January&nbsp;5, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000110465921000921/tm211620d1_ex3-2.htm">Amended and Restated Bylaws of Eledon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the registrant&#146;s current report
 on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on January&nbsp;5, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-ex4_1.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the registrant&#146;s
 current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on May&nbsp;7, 2024) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d822027dex51.htm">Opinion of O&#146;Melveny&nbsp;&amp; Myers LLP ** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-ex10_1.htm">Securities Purchase Agreement, dated May&nbsp;
6, 2024, by and among Eledon Pharmaceuticals, Inc. and each purchaser identified on Schedule I thereto (incorporated by reference to Exhibit 10.1 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> filed on May&nbsp;7, 2024) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-ex10_2.htm">Registration Rights Agreement, dated May&nbsp;
6, 2024, by and among Eledon Pharmaceuticals, Inc. and certain purchasers (incorporated by reference to Exhibit 10.2 to the registrant&#146;s current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)
</FONT> filed on May&nbsp;7, 2024) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d822027dex231.htm">Consent of KMJ Corbin&nbsp;&amp; Company LLP, independent registered public accounting firm ** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d822027dex51.htm">Consent of O&#146;Melveny&nbsp;&amp; Myers LLP (included in legal opinion filed as Exhibit 5.1) ** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d822027ds3.htm#sig">Power of Attorney (included on signature page) ** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d822027dexfilingfees.htm">Filing Fee Table ** </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant
hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Filing Fee Tables&#148; table in the effective
registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in
the registration statement or any material change to such information in the registration statement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provided, however</I>, That: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement,
or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration
statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(B) Each prospectus
required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the
information required by Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of
the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective
date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided,
however,</I> that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<I> bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in
the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the
payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Irvine, State of California, on May
24, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELEDON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David-Alexandre C. Gros, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David-Alexandre C. Gros, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
dates indicated, each of whom also constitutes and appoints David-Alexandre C. Gros, M.D. and Paul Little, and each of them singly, his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT>
and agent, for him, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, and to file the same and all exhibits thereto
and any other documents in connection therewith with the Securities and Exchange Commission, granting unto each <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do
and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ David-Alexandre C. Gros, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David-Alexandre C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Paul Little</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paul Little</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Keith A. Katkin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Keith A. Katkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jan Hillson, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jan Hillson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Allan Kirk, M.D., PhD</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Allan Kirk, M.D., PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ June Lee, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June Lee, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ John S. McBride</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John S. McBride</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Walter Ogier</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Walter Ogier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Steven Perrin, PhD</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Steven Perrin, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">President, Chief Scientific Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James Robinson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Robinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 24, 2024</TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d822027dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822027g0524110413449.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">O&#146;Melveny&nbsp;&amp; Myers LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">610 Newport
Center Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Newport Beach, CA 92660-6429</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">T: +1 949 823 6900</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="left">F: +1 949 823 6994</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">omm.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">File Number: 0241090-00007</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;24, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eledon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19800 MacArthur Blvd., Suite 250 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California 92612 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I><U>Registration of Resale of 21,100,000 Shares of Common Stock of Eledon Pharmaceuticals, Inc.
Offered by Selling Stockholders</U></I></B><B> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have acted as counsel to Eledon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), in
connection with the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed by the Company under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), with the Securities and Exchange Commission on
the date hereof (the &#147;<B>Registration Statement</B>&#148;). The Registration Statement relates to the offering and sale from time to time of up to 21,100,00 shares of the Company&#146;s common stock, $0.001 par value per share (&#147;<B>Common
Stock</B>&#148;), by the selling stockholders identified in the Registration Statement (collectively with any of such stockholders&#146; transferees, pledgees, donees or successors, the &#147;<B>Selling Stockholders</B>&#148;), which shares were
previously issued pursuant to a Securities Purchase Agreement (the &#147;<B>Purchase Agreement</B>&#148;) between the Company and the Selling Stockholders and consist of (i) 13,110,484 shares of Common Stock (the &#147;<B>Shares</B>&#148;) and (ii)
7,989,516 shares of Common Stock (the &#147;<B>Warrant Shares</B>&#148;) issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of Common Stock (the &#147;<B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#148;)<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our capacity as such counsel, we have
examined originals or copies of those corporate and other records and documents we considered appropriate. As to relevant factual matters, we have relied upon, among other things, the Company&#146;s factual representations in a Company certificate
dated as of the date hereof. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with originals of all documents submitted to us as copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the basis of such examination, our reliance upon the assumptions in this opinion and our consideration of those questions
of law we considered relevant, and subject to the limitations and qualifications in this opinion, we are of the opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Shares have been duly authorized by all necessary corporate action on the part of the Company and are
validly issued, fully paid and non-assessable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized by all necessary
corporate action on the part of the Company and constitute the legally valid and binding obligation of the Company, enforceable against the Company in accordance with their </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Austin &#149; Century City
&#149; Dallas &#149; Houston &#149; Los Angeles &#149; Newport Beach &#149; New York &#149; San Francisco &#149; Silicon Valley &#149; Washington, DC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Beijing &#149; Brussels &#149; Hong Kong &#149; London &#149; Seoul &#149; Shanghai &#149; Singapore &#149; Tokyo </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g822027g0524110413449.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors&#146; rights generally (including, without limitation,
fraudulent conveyance laws) and by general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief,
regardless of whether considered in a proceeding in equity or at law. Upon the issuance, payment for and delivery of the Warrant Shares in accordance with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Warrant Shares will be
validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our opinion in
paragraph 2 assumes that, upon issuance of the Warrant Shares the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the
Company&#146;s Restated Certificate of Incorporation, as amended. The law governed by this opinion letter is limited to the present law of the State of New York and the current General Corporation Law of the State of Delaware. We express no opinion
herein as to the laws of any other jurisdiction and no opinion regarding the statutes, administrative decisions, rules, regulations or requirements of any county, municipality, subdivision or local authority of any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, the prospectus included in the Registration Statement or any
prospectus supplement, other than as expressly stated herein with respect to the Shares and the Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hereby
consent to the use of this opinion as an exhibit to the Registration Statement and to the reference to this firm under the heading &#147;Legal Matters&#148; in the prospectus constituting part of the Registration Statement. In giving this consent,
we do not thereby admit that we are included in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations promulgated thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Respectfully submitted,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ O&#146;Melveny&nbsp;&amp; Myers LLP</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d822027dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of Eledon
Pharmaceuticals, Inc. of our report dated March&nbsp;28, 2024 (which contains an explanatory paragraph describing conditions that raise substantial doubt about Eledon Pharmaceuticals, Inc.&#146;s ability to continue as a going concern) relating to
the financial statements of Eledon Pharmaceuticals, Inc., appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Eledon Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also consent to the reference to us under the heading &#147;Experts&#148; in the prospectus, which is part of this registration statement.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ KMJ Corbin&nbsp;&amp; Company LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Irvine, California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">May&nbsp;24, 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d822027dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eledon
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Calculation<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered (1)<BR>(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Share (3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum<BR>Aggregate<BR>Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Amount of<BR>Registration<BR>Fee</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;Stock, $0.001&nbsp;par&nbsp;value</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">21,100,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">$3.09</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">&#8201;$65,199,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00014760</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#8201;$9,623.37</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#8201;$65,199,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#8201;$9,623.37</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$9,623.37</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock will be offered for resale by the selling stockholders pursuant to the prospectus
constituting part of the registration statement to which this exhibit is attached. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this registration statement also covers any additional number of
shares of common stock issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this registration statement. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This registration statement registers the resale of 21,100,000 shares of the Registrant&#146;s common stock,
which consists of 13,110,484 shares of common stock held by the selling stockholders and 7,989,516 shares of common stock issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of
common stock held by certain selling stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities
Act, based on the average of the high and low price per share of the Registrant&#146;s common stock as reported on The Nasdaq Capital Market on May&nbsp;21, 2024. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g822027g0524110413449.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g822027g0524110413449.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 '@# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g822027g95p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g822027g95p03.jpg
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M 0$! 0$!_\  $0@ 4 $] P$1  (1 0,1 ?_$ !\   (" P$  P$
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M2CI2D^]V+O':4[4H'6C5TH-JV]LS;:STJGZ\JQ4;7&&*_5UCF3=DL]H)1B2
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MG=7=>CI2CI2J"_C"_OC>''Y$[_\ GW$Z5Z6.2O,?*F3>%&V9KBG=N#: NW;
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MI8V(,%BWV'3]B@=6RRV&8-MMENA-%2B22AF/'8:0IQUUQ02 %NNKR5*-=+N
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MQ/YAE+_O G/U3=*AU'_O_P#C_P#:C[<:V)_,,I?]X$Y^J;I3J/\ W_\ Q_\
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MZ&4'1)"?5AO*%*J"001S!S2T^/?8*[7O'2):(P'C_C8;ULDBWYQ#<-F,7R7
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MN^I#$Y7M)L'W8HI_)#*.U39+!US&7=;4&86J&&?P4C@B/=FT)]2+.4D8#@2
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MWD#/O[*W,,[QO$&Y X@K52MM;-Y#EH;<03Q'#:=V2*Y 1KLZWAM5*NX ]6(
M+6>!)'+D.SW>\'@^NP,6)--.VF2):9DR5-T\S@#OR,>[)&>'8.-1"XN:<W%L
M?P]>V-(KI$L?O6\:;[B-08UXAN0U*7L6Q;PY*M0:J/\ B#<9]S!(W+8'!Y4E
M#*)34J'+4I++OKZ5(D=8"#D#<.? !/T]_C4_.%'< XR\C0^L-/:IMQVQ[5!:
MA"D=ETA-#O(\CI@C6 U>#G*KM^65KT ;0+<R=F+##JV>F12YV3 )20L2<.@R
M)J%14DC)/(G@>&#SY<3D>6<<,\QE8''?0F[C'9W[6NUM1T,C9-]<*;51^1P?
M3A/.*R>V=7!3FS:-M+5<!XXF.P%M5HUC?[%*I[Y-I#+EJ&@8;RFXL]USJ@Y#
MR%5!&\H$X"LC.,\SD'X@<O.F$X[S' [ 7*5W?9;6UTQO9*XR.:'W(GD]BT>C
MT?03&F?H7](UV?XC_HC#Z/55<S,^]8LWP;_2O5:INJ\//(Q\<X[>^HI<U+GL
M[8M0[?-XYSZPV%I[AQ<;#NLUSEU3KHM>['%I! F!;D<3*YR'(:G;^ETO6D5*
MR"-Q1827=>0]HKKXZUNR:Q'C.N.?/[_?M^%5 ]H#!/#!/#AVD9//ECMQGD:A
MEW(;)P3OO #?.K.UKQ-U#MVVRJ5#EVG9?'7CB$$T33%! '@IJRG2^T!5'$CS
M%^-#AK]>K%%JIHY?I9$G(LQ@9%K8(T1PJ202H%9//M/$]F.?T\L=^0"Y#D<(
M+2^Z'VQ"\481DBA&I.X8T6)L0I+P\6Z3K7&IL<V1FMM*C0G"#D:0W"1)=:5+
M7'?2QAQ33F$J@/9/Z2?DNM$<AN2';"W"1N6L^YEHBFZEO5"L]FJ@:'RRU!B0
MS9ZI ,SF:Q?]%;OBUTC7[%7[D(]W,1F*#=6;57B$R> /"H)&&I<M50%#&Z>>
M#ZIX\<9X Y[<<N/E67=J,)(#EN66=0KW.UP&D7_7".%\#=LK8LDBRS%HJD;M
MG:M^S MS:#.B)]S<#)UXFQ+R*D$8=M(57"@LUI]]179D#>P<XQQX\,X[>\]O
#"O_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
